Возможности литолитической терапии камней различного состава: обзор потенциальных растворителей и перспективы дальнейших разработок

1. Ahmed S, Hasan MM, Khan H, Mahmood ZA, Patel S. The mechanistic insight of polyphenols in calcium oxalate urolithiasis mitigation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2018;106:1292-1299. doi:10.1016/j.biopha.2018.07.080

2. Kim HJ, Oh SH. Comprehensive prediction of urolithiasis based on clinical factors, blood chemistry and urinalysis: UROLITHIASIS score. Scientific reports. 2023;13(1):14885. doi:10.1038/s41598-023-42208-9

3. Gadzhiev N, Prosyannikov M, Malkhasyan V et al. Urolithiasis prevalence in the Russian Federation: analysis of trends over a 15-year period. World journal of urology. 2021;39(10):3939-3944. doi:10.1007/s00345-021-03729-y

4. Li S, Huang X, Liu J et al. Trends in the Incidence and DALYs of Urolithiasis From 1990 to 2019: Results From the Global Burden of Disease Study 2019. Frontiers in public health. 2022;10:825541. doi:10.3389/fpubh.2022.825541

5. Tan S, Yuan D, Su H et al. Prevalence of urolithiasis in China: a systematic review and meta-analysis. BJU international. 2024;133(1):34-43. doi:10.1111/bju.16179

6. Heers H, Stay D, Wiesmann T, Hofmann R. Urolithiasis in Germany: Trends from the National DRG Database. Urologia internationalis. 2022;106(6):589-595. doi:10.1159/000520372

7. Zi H, Liu MY, Luo LS et al. Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021. Military Medical Research. 2024;11(1):64. doi:10.1186/s40779-024-00569-w

8. Sánchez C, Larenas F, Arroyave JS et al. Artificial Intelligence in Urology: Application of a Machine Learning Model to Predict the Risk of Urolithiasis in a General Population. Journal of endourology. 2024;38(8):712-718. doi:10.1089/end.2023.0702

9. Ma Y, Cheng C, Jian Z et al. Risk factors for nephrolithiasis formation: an umbrella review. International journal of surgery (London, England). 2024;110(9):5733-5744. doi:10.1097/JS9.0000000000001719

10. Lieske JC, Rule AD, Krambeck AE et al. Stone composition as a function of age and sex. Clinical journal of the American Society of Nephrology : CJASN. 2014;9(12):2141-2146. doi:10.2215/CJN.05660614

11. Stamatelou K, Goldfarb DS. Epidemiology of Kidney Stones. Healthcare (Basel, Switzerland). 2023;11(3). doi:10.3390/healthcare11030424

12. Morales Martínez A, Melgarejo Segura MT, Cano García MC. Medical management of uric acid renal stones, case description. Archivos espanoles de urologia. 2021;74(4):442-445.

13. Robinson TE, Hughes EAB, Wiseman OJ, Stapley SA, Cox SC, Grover LM. Hexametaphosphate as a potential therapy for the dissolution and prevention of kidney stones. Journal of materials chemistry B. 2020;8(24):5215-5224. doi:10.1039/d0tb00343c

14. Bres-Niewada E, Dybowski B, Radziszewski P. Predicting stone composition before treatment - can it really drive clinical decisions? Central European journal of urology. 2014;67(4):392-396. doi:10.5173/ceju.2014.04.art15

15. Vella M, Karydi M, Coraci G, Oriti R, Melloni D. Pathophysiology and clinical aspects of urinary lithiasis. Urologia internationalis. 2007;79 Suppl 1:26-31. doi:10.1159/000104438

16. Wang Z, Zhang Y, Zhang J, Deng Q, Liang H. Recent advances on the mechanisms of kidney stone formation (Review). International journal of molecular medicine. 2021;48(2). doi:10.3892/ijmm.2021.4982

17. Grases F, Costa-Bauzá A, Gomila I, Ramis M, García-Raja A, Prieto RM. Urinary pH and renal lithiasis. Urological research. 2012;40(1):41-46. doi:10.1007/s00240-011-0389-3

18. Prosyannikov M.Yu., Anokhin N.V., Golovanov S.A., Sivkov A.V., Apolikhin O.I. The effect of urine pH on the processes of stone formation in urolithiasis. Experimental and Clinical Urology. 2020;(3):72–78. Russian (Просянников М.Ю., Анохин Н.В., Голованов С.А., Сивков А.В., Аполихин О.И. Влияние рН мочи на процессы камнеобразования при уролитиазе. Экспериментальная и клиническая урология. 2020;(3):72–78).

19. Gadzhiev N.K., Gelig V.A., Kutina A.V. et al. Urine acid-base state (pH): regulation mechanism and its role in the metaphylaxis of urolithiasis. Bulletin of Urology. 2022;10(4):120-140. doi:https://doi.org/10.21886/2308-6424-2022-10-4-120-140. Russian (Гаджиев Н.К., Гелиг В.А., Кутина А.В. и др. Кислотно-основное состояние (pH) мочи: механизм регуляции и его роль в метафилактике мочекаменной болезни. Вестник урологии. 2022;10(4):120-140. doi:https://doi.org/10.21886/2308-6424-2022-10-4-120-140).

20. Moe OW. Kidney stones: pathophysiology and medical management. Lancet (London, England). 2006;367(9507):333-344. doi:10.1016/S0140-6736(06)68071-9

21. Wigner P, Bijak M, Saluk-Bijak J. Probiotics in the Prevention of the Calcium Oxalate Urolithiasis. Cells. 2022;11(2). doi:10.3390/cells11020284

22. Moretto S, Saita A, Scoffone CM et al. Ureteral stricture rate after endoscopic treatments for urolithiasis and related risk factors: systematic review and meta-analysis. World journal of urology. 2024;42(1):234. doi:10.1007/s00345-024-04933-2

23. Edmonds VS, Wymer KM, Humphreys MR, Stern KL. Trends in Patient Complexity, Practice Setting, and Surgeon Reimbursement for Urolithiasis: Do Rural Urologists Pay the Price? Urology. 2024;192:30-35. doi:10.1016/j.urology.2024.07.027

24. Antonelli JA, Maalouf NM, Pearle MS, Lotan Y. Use of the National Health and Nutrition Examination Survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. European Urology. 2014;66(4):724-729. doi:10.1016/j.eururo.2014.06.036

25. Gonzalez RD, Whiting BM, Canales BK. The history of kidney stone dissolution therapy: 50 years of optimism and frustration with renacidin. Journal of endourology. 2012;26(2):110-118. doi:10.1089/end.2011.0380

26. Gridley CM, Sourial MW, Lehman A, Knudsen BE. Medical dissolution therapy for the treatment of uric acid nephrolithiasis. World journal of urology. 2019;37(11):2509-2515. doi:10.1007/s00345-019-02688-9

27. Bazhenov I.V., Zyryanov A.V., Danilov V.O. et al. Stone-dissolving therapy for coral-like calculi. Consilium Medicum. 2019;21(7):64–68. Russian (Баженов И.В., Зырянов А.В., Данилов В.О. и др. Камнерастворяющая терапия коралловидных конкрементов. Consilium Medicum. 2019;21(7):64–68).

28. Barbera M, Tsirgiotis A, Barbera M, Paola Q. The importance of potassium citrate and potassium bicarbonate in the treatment of uric acid renal stones. Archivio italiano di urologia, andrologia : organo ufficiale

29. Tsaturyan A, Bokova E, Bosshard P, Bonny O, Fuster DG, Roth B. Oral chemolysis is an effective, non-invasive therapy for urinary stones suspected of uric acid content. Urolithiasis. 2020;48(6):501-507. doi:10.1007/s00240-020-01204-8

30. Al’-Shukri SK, Slesarevskaya MN, Kuz’min IV. Litholytic therapy for urate nephrolithiasis. Urologiia. 2016;(2):23–27.

31. Konstantinova OV, Yanenko EK. Experience of use of Blemaren® in the treatment of patients in uric acid and calcium oxalate urolithiasiS. Urologiia. 2015;(5):22-24.

32. Hsi RS, Crivelli JJ, Yan PL, Shahinian V, Hollingsworth JM. Comparison of Class-Specific Side Effects Across Preventative Pharmacologic Therapies for Kidney Stone Disease. Urology practice. 2024;11(1):172-178. doi:10.1097/UPJ.0000000000000470

33. Costa-Bauzá A, Calvó P, Hernández Y, Grases F. Efficacy of Theobromine and Its Metabolites in Reducing the Risk of Uric Acid Lithiasis. International journal of molecular sciences. 2023;24(13). doi:10.3390/ijms241310879

34. Julià F, Costa-Bauza A, Berga F, Grases F. Effect of theobromine on dissolution of uric acid kidney stones. World journal of urology. 2022;40(8):2105-2111. doi:10.1007/s00345-022-04059-3

35. Hernandez Y, Costa-Bauza A, Calvó P, Benejam J, Sanchis P, Grases F. Comparison of Two Dietary Supplements for Treatment of Uric Acid Renal Lithiasis: Citrate vs. Citrate + Theobromine. Nutrients. 2020;12(7). doi:10.3390/nu12072012

36. Solak V, Gökce Mİ, Yaman Ö. Potassium citrate vs. hydrochlorothiazide to reduce urinary calcium excretion in calcium oxalate stone patients with hypercalciuria: a prospective randomized study. International urology and nephrology. 2021;53(9):1791-1796. doi:10.1007/s11255-021-02879-7

37. Unno R, Taguchi K, Okada A et al. Potassium-sodium citrate prevents the development of renal microcalculi into symptomatic stones in calcium stone-forming patients. International journal of urology : official journal of the Japanese Urological Association. 2017;24(1):75-81. doi:10.1111/iju.13242

38. Ansari R, Karimzade I, Nimrouzi M, Ezatzadegan S, Hosseini MM, Zarshenas MM. Safety and efficacy of a polyherbal formulation from traditional Persian medicine in patients with calcium kidney stones: A randomized, double-blinded clinical trial. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. 2024;29:12. doi:10.4103/jrms.jrms_670_22

39. Wu F, Cheng Y, Zhou J et al. Zn(2+) regulates human oxalate metabolism by manipulating oxalate decarboxylase to treat calcium oxalate stones. International journal of biological macromolecules. 2023;234:123320. doi:10.1016/j.ijbiomac.2023.123320

40. Malieckal DA, Ganesan C, Mendez DA, Pao AC. Breaking the Cycle of Recurrent Calcium Stone Disease. Advances in kidney disease and health. 2023;30(2):164-176. doi:10.1053/j.akdh.2022.12.004

41. Atanassova SS. Influence of the lysine on the calcium oxalate renal calculi. International urology and nephrology. 2014;46(3):593-597. doi:10.1007/s11255-013-0532-x

42. Ravikumar Y, Begum RF, Velmurugan R. Oxalobacter formigenes reduce the risk of kidney stones in patients exposed to oral antibiotics: a case-control study. International urology and nephrology. 2021;53(1):13-20. doi:10.1007/s11255-020-02627-3

43. Daniel SL, Moradi L, Paiste H et al. Forty Years of Oxalobacter formigenes, a Gutsy Oxalate-Degrading Specialist. Applied and environmental microbiology. 2021;87(18):e0054421. doi:10.1128/AEM.00544-21

44. Sidhu H, Hoppe B, Hesse A et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet. 1998;352(9133):1026-1029. doi:10.1016/S0140-6736(98)03038-4

45. Sidhu H, Enatska L, Ogden S, Williams WN, Allison MJ, Peck AB. Evaluating Children in the Ukraine for Colonization With the Intestinal Bacterium Oxalobacter formigenes, Using a Polymerase Chain Reaction-based Detection System. Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology. 1997;2(2):89-97. doi:10.1054/MODI00200089

46. Jonsson S, Ricagno S, Lindqvist Y, Richards NGJ. Kinetic and mechanistic characterization of the formyl-CoA transferase from Oxalobacter formigenes. The Journal of biological chemistry. 2004;279(34):36003-36012. doi:10.1074/jbc.M404873200

47. Hiremath S, Viswanathan P. Oxalobacter formigenes: A new hope as a live biotherapeutic agent in the management of calcium oxalate renal stones. Anaerobe. 2022;75:102572. doi:10.1016/j.anaerobe.2022.102572

48. Chmiel JA, Carr C, Stuivenberg GA et al. New perspectives on an old grouping: The genomic and phenotypic variability of Oxalobacter formigenes and the implications for calcium oxalate stone prevention. Frontiers in microbiology. 2022;13:1011102. doi:10.3389/fmicb.2022.1011102

49. Ellis ML, Dowell AE, Li X, Knight J. Probiotic properties of Oxalobacter formigenes: an in vitro examination. Archives of microbiology. 2016;198(10):1019-1026. doi:10.1007/s00203-016-1272-y

50. Siener R, Bangen U, Sidhu H, Hönow R, von Unruh G, Hesse A. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney international. 2013;83(6):1144-1149. doi:10.1038/ki.2013.104

51. Verhulst A, Dehmel B, Lindner E, Akerman ME, D’Haese PC. Oxalobacter formigenes treatment confers protective effects in a rat model of primary hyperoxaluria by preventing renal calcium oxalate deposition. Urolithiasis. 2022;50(2):119-130. doi:10.1007/s00240-022-01310-9

52. Taheri H, Feizabadi MM, Keikha R, Afkari R. Therapeutic effects of probiotics and herbal medications on oxalate nephrolithiasis: a mini systematic review. Iranian journal of microbiology. 2024;16(1):4-18. doi:10.18502/ijm.v16i1.14866

53. Milliner D, Hoppe B, Groothoff J. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Urolithiasis. 2018;46(4):313-323. doi:10.1007/s00240-017-0998-6

54. Ariceta G, Collard L, Abroug S et al. ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria. Pediatric nephrology (Berlin, Germany). 2023;38(2):403-415. doi:10.1007/s00467-022-05591-5

55. Quintero E, Bird VY, Liu H et al. A Prospective, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Using an Orally Administered Oxalate Decarboxylase (OxDC). Kidney360. 2020;1(11):1284-1290. doi:10.34067/KID.0001522020

56. Saso L, Valentini G, Leone MG, Grippa E, Silvestrini B. Development of an in vitro assay for the screening of substances capable of dissolving calcium oxalate crystals. Urologia internationalis. 1998;61(4):210-214. doi:10.1159/000030331

57. Burns JR, Cargill JG 3rd. Kinetics of dissolution of calcium oxalate calculi with calcium-chelating irrigating solutions. The Journal of urology. 1987;137(3):530-533. doi:10.1016/s0022-5347(17)44100-0

58. Abeshouse BS, Weinberg T. Experimental study of solvent action of versene on urinary calculi. The Journal of urology. 1951;65(2):316-335. doi:10.1016/S0022-5347(17)68486-6

59. Zhang X bo, Wang Z ping, Duan J min, et al. Urothelial injury to the rabbit bladder caused by calcium dissolving agents including two new citrate solutions. Urological research. 2005;33(4):309-313. doi:10.1007/s00240-005-0479-1

60. Kane MH, Rodman JS, Horten B, Reckler J, Marion D, Vaughan EDJ. Urothelial injury from ethylenediaminetetraacetic acid used as an irrigant in the urinary tract. The Journal of urology. 1989;142(5):1359-1360. doi:10.1016/s0022-5347(17)39098-5

61. Shevyrin AA, Demidov VI, Strelnikov AI, Berezin BD, Kustov AV. Effect of Trilon B solution on the mucous membrane of the urinary system organs in an experiment. Bulletin of the Ivanovo Medical Academy. 2010;15(4):15-18. Russian (Шевырин А.А., Демидов В.И., Стрельников А.И., Березин Б.Д., Кустов А.В. Воздействие раствора Трилона Б на слизистую оболочку органов мочевой системы в эксперименте. Вестник Ивановской медицинской академии. 2010;15(4):15-18).

62. Shevyrin AA. Litholysis of urinary system calculi with Trilon B complexon solution (medical, chemical, and biological aspects). Abstract. Dissertation of a Candidate of Medical Sciences. 2008. Russian (Шевырин А.А. Литолиз конкрементов мочевыделительной системы раствором комплексона Трилон Б (медицинские, химические и биологические аспекты). Автореф. дисс. к.м.н. 2008).

63. Kustov AV, Berezin BD, Trostin VN. A method for removing oxalate urinary stones in patients with urolithiasis. Published online 2009. Russian (Кустов А.В., Березин Б.Д., Тростин В.Н. Способ удаления оксалатных мочевых камней у больных уролитиазом. Published online 2009).

64. Timmermann A, Kallistratos G. Modern aspects of chemical dissolution of human renal calculi by irrigation. The Journal of urology. 1966;95(4):469-475. doi:10.1016/S0022-5347(17)63480-3

65. Adelman A, Shilo Y, Modai J, Leibovici D, Dror I, Berkowitz B. Do organic substances act as a degradable binding matrix in calcium oxalate kidney stones? BMC urology. 2021;21(1):46. doi:10.1186/s12894-021-00818-3

66. Zhang J, Wang S, Hong J, Liu C, Jiang Y. New potential solutions for the chemolysis of urinary phosphate calculi determined by an in vitro study. Urolithiasis. 2015;43(2):147-153. doi:10.1007/s00240-014-0745-1

67. Ebel A, Kuo JC. Post mortem findings in a patient treated with renacidin for unilateral renal calculosis. Proceedings Clinical Spinal Cord Injury Conference. 1964;13:93-97.

68. Kohler FP. Renacidin and tissue reaction. The Journal of urology. 1962;87:102-108. doi:10.1016/S0022-5347(17)64915-2

69. Nemoy NJ, Staney TA. Surgical, bacteriological, and biochemical management of «infection stones». JAMA. 1971;215(9):1470-1476.

70. Xiang-bo Z, Zhi-ping W, Jian-min D, Jian-zhong L, Bao-liang M. New chemolysis for urological calcium phosphate calculi – a study in vitro. BMC urology. 2005;5:9. doi:10.1186/1471-2490-5-9

71. Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stones – pathogenesis, microbiology, and management strategies. Nature reviews Urology. 2014;11(6):333-341. doi:10.1038/nrurol.2014.99

72. Van de Perre E, Reichman G, De Geyter D, Geers C, Wissing KM, Letavernier E. Encrusted Uropathy: A Comprehensive Overview-To the Bottom of the Crust. Frontiers in medicine. 2020;7:609024. doi:10.3389/fmed.2020.609024

73. Gadzhiev NK, Malikiev IE, Obidnyak VM et al. The Problem of Clinical Diagnostics and Treatment of Incrusting Cystitis. Urology. 2022;(5):142-146. Russian (Гаджиев НК, Маликиев ИЕ, Обидняк ВМ, и др. Проблема клинической диагностики и лечения инкрустирующего цистита. Урология. 2022;(5):142-146).

74. Sabiote L, Emiliani E, Kanashiro AK et al. Oral Acidification with l-Methionine as a Noninvasive Treatment for Encrusted Uropathy. Journal of endourology case reports. 2020;6(3):143-146. doi:10.1089/cren.2019.0164

75. Tanaka T, Yamashita S, Mitsuzuka K et al. Encrusted cystitis causing postrenal failure. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2013;19(6):1193-1195. doi:10.1007/s10156-013-0603-z

76. Allam EAH, Sabra MS. Plant-based therapies for urolithiasis: a systematic review of clinical and preclinical studies. International urology and nephrology. 2024;56(12):3687-3718. doi:10.1007/s11255-024-04148-9

77. Morgan MSC, Pearle MS. Medical management of renal stones. BMJ (Clinical research ed). 2016;352:i52. doi:10.1136/bmj.i52

78. Pearle MS, Goldfarb DS, Assimos DG et al. Medical management of kidney stones: AUA guideline. The Journal of urology. 2014;192(2):316-324. doi:10.1016/j.juro.2014.05.006

79. Jung H, Andonian S, Assimos D et al. Urolithiasis: evaluation, dietary factors, and medical management: an update of the 2014 SIU-ICUD international consultation on stone disease. World journal of urology. 2017;35(9):1331-1340. doi:10.1007/s00345-017-2000-1